600422 Stock Overview
A pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
KPC Pharmaceuticals,Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.12 |
| 52 Week High | CN¥24.11 |
| 52 Week Low | CN¥11.92 |
| Beta | 0.20 |
| 1 Month Change | -0.29% |
| 3 Month Change | 1.54% |
| 1 Year Change | -19.59% |
| 3 Year Change | 39.76% |
| 5 Year Change | 70.18% |
| Change since IPO | 283.78% |
Recent News & Updates
Is There An Opportunity With KPC Pharmaceuticals,Inc.'s (SHSE:600422) 35% Undervaluation?
Dec 30
Does KPC PharmaceuticalsInc (SHSE:600422) Have A Healthy Balance Sheet?
Dec 12Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)
Nov 18Recent updates
Is There An Opportunity With KPC Pharmaceuticals,Inc.'s (SHSE:600422) 35% Undervaluation?
Dec 30Does KPC PharmaceuticalsInc (SHSE:600422) Have A Healthy Balance Sheet?
Dec 12Investors Holding Back On KPC Pharmaceuticals,Inc. (SHSE:600422)
Nov 18Is KPC Pharmaceuticals,Inc. (SHSE:600422) Trading At A 42% Discount?
Sep 30These 4 Measures Indicate That KPC PharmaceuticalsInc (SHSE:600422) Is Using Debt Safely
Sep 11KPC PharmaceuticalsInc (SHSE:600422) Will Pay A Larger Dividend Than Last Year At CN¥0.20
Jul 25Investors Still Waiting For A Pull Back In KPC Pharmaceuticals,Inc (SHSE:600422)
Jun 25We Think KPC PharmaceuticalsInc (SHSE:600422) Can Stay On Top Of Its Debt
Jun 04KPC PharmaceuticalsInc's (SHSE:600422) Profits May Not Reveal Underlying Issues
Mar 28Shareholder Returns
| 600422 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.5% | -0.8% | -2.1% |
| 1Y | -19.6% | -0.5% | 11.6% |
Return vs Industry: 600422 underperformed the CN Pharmaceuticals industry which returned -0.5% over the past year.
Return vs Market: 600422 underperformed the CN Market which returned 11.6% over the past year.
Price Volatility
| 600422 volatility | |
|---|---|
| 600422 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 3.3% |
Stable Share Price: 600422 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600422's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 5,051 | n/a | www.kpc.com.cn |
KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotic, immunosuppressive, and others. The company provides medicine and food, skin care, oral care, private care, and time-honored food series; and other products, such as oral medication and injections.
KPC Pharmaceuticals,Inc. Fundamentals Summary
| 600422 fundamental statistics | |
|---|---|
| Market cap | CN¥12.96b |
| Earnings (TTM) | CN¥648.08m |
| Revenue (TTM) | CN¥8.40b |
20.0x
P/E Ratio1.5x
P/S RatioIs 600422 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600422 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.40b |
| Cost of Revenue | CN¥4.75b |
| Gross Profit | CN¥3.65b |
| Other Expenses | CN¥3.00b |
| Earnings | CN¥648.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.86 |
| Gross Margin | 43.46% |
| Net Profit Margin | 7.71% |
| Debt/Equity Ratio | 10.4% |
How did 600422 perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 05:48 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KPC Pharmaceuticals,Inc. is covered by 26 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Pei Hui Tang | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |